Patents by Inventor John R. Langridge

John R. Langridge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions containing insulin
    Publication number: 20020115592
    Abstract: A pharmaceutical composition comprising insulin and optionally aprotinin, in a substantially non-aqueous hydrophilic medium comprising an alcohol and a cosolvent, in association with a medium chain partial glyceride, optionally in admixture a long-chain PEG species.
    Type: Application
    Filed: June 4, 2001
    Publication date: August 22, 2002
    Applicant: Provalis UK Limited
    Inventors: Roger C. New, John R. Langridge, Christopher J. Smith
  • Sustained release ranolazine formulations
    Publication number: 20020090396
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
    Type: Application
    Filed: October 19, 2001
    Publication date: July 11, 2002
    Applicant: CV Therapeutics, Inc.
    Inventors: Andrew A. Wolff, Fiona Baker, John R. Langridge
  • Sustained release ranolazine formulations
    Publication number: 20020004506
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
    Type: Application
    Filed: August 9, 2001
    Publication date: January 10, 2002
    Applicant: CV Therapeutics, Inc.
    Inventors: Andrew A. Wolff, Fiona Baker, John R. Langridge
  • Long acting calcium channel blocker composition
    Patent number: 5209933
    Abstract: There is disclosed an improved long acting sustained release pharmaceutical composition for dihydropyridine calcium channel blockers wherein the calcium channel blocker and a pH-dependent binder, which are intimately admixed in essentially spherically shaped non-rugose particles of up to 1.2 mm in diameter, are provided with a coating to obtain slow, sustained release of a safe, therapeutically effective amount of the calcium channel blocker over a period of at least about 24 hours. Thus, the improved pharmaceutical composition for a dihydropyridine calcium channel blockers is suitable for once daily administration.
    Type: Grant
    Filed: September 13, 1991
    Date of Patent: May 11, 1993
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Calum B. MacFarlane, Alastair B. Selkirk, John R. Langridge, Michael J. Dey
  • Medicaments in sustained release unit dose form
    Patent number: 4806361
    Abstract: Sustained-release compositions for oral administration comprising medicament-coated nonpareils surrounded by a sustaining coating of at least three admixed polymers afford exceptionally good plasma levels of the medicament.
    Type: Grant
    Filed: May 24, 1985
    Date of Patent: February 21, 1989
    Assignee: Sterling Drug Inc.
    Inventors: Paul J. Harrison, John R. Langridge, Christopher J. Potter
  • Unit dosage form of sparingly soluble medicaments
    Patent number: 4717569
    Abstract: Pharmaceutical compositions of a polycyclic medicament having very low solubility in water and aqueous media comprise a plurality of beads, each bead comprising particles of finely divided medicament, which may have a particulate core or filler, bound together by a water soluble binder.
    Type: Grant
    Filed: May 24, 1985
    Date of Patent: January 5, 1988
    Assignee: Sterling Drug Inc.
    Inventors: Paul J. Harrison, John R. Langridge, Christopher J. Potter